Drug-Eluting Stents - Market Insights, Competitive Landscape, and Market Forecast - 2030

Drug-Eluting Stents Market by Type (Coronary Stenting and Peripheral Stenting), Scaffold (Platinum-Chromium, Cobalt-Chromium, Nitinol, and Others), Coating (Polymer-based Coating [Biodegradable and Non-biodegradable] and Polymer-free Coating), Drug Type (Everomilus, Paclitaxel, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing cases of cardiovascular disorders and the rising product developmental activities worldwide

The drug-eluting stents market was valued at USD 2.40 billion in 2023, growing at a CAGR of 7.88% during the forecast period from 2024 to 2030 to reach USD 3.78 billion by 2030. The drug-eluting stents market is observing substantial market growth primarily owing to the increasing cases of cardiovascular disorders including atrial fibrillation and coronary artery disease (CAD), peripheral artery disease (PAD), innovative product developmental activities by regulatory bodies, and the rising adoption of minimally invasive techniques that are expected to escalate the overall growth of the drug-eluting stents market during the forecast period from 2024 to 2030.

Drug-Eluting Stents Market Dynamics:

As per data provided by the World Heart Report (2023), in 2021, it was stated that more than half a billion people were living with cardiovascular diseases globally. Further, according to recent data provided by the American Heart Association (2023), it is estimated that by 2030 over 12 million people will have atrial fibrillation globally.

According to British Heart Foundation, Global Heart & Circulatory Diseases Factsheet (2024), it stated that around 200 million people are living with coronary artery disease (CAD) around the world.

As per data by the American Heart Association (2023), around 200 million live with peripheral artery disease (PAD) globally on average. Also, as per the Global Burden of Disease (2019), there were 56.4 million prevalent cases of PAD among those aged 40 to 70, worldwide in 2019.

Thus, the rising instances of cardiovascular conditions are driving a significant increase in demand for drug-eluting stents. As these conditions become more widespread globally, the need for effective, minimally invasive treatments like stenting is growing. Advances in stent technology, along with the increasing burden of heart and circulatory diseases, are making stents a vital component in treating these conditions, enhancing their role in both preventive and therapeutic healthcare strategies.

Increased product developmental activities by regulatory bodies worldwide is also slated to drive the market growth for drug-eluting stents. For example, in May 2022, Medtronic announced that it received the U.S. Food and Drug Administration (FDA) approval for the Onyx Frontier(TM) drug-eluting stent (DES).

Hence, the interplay of all the above-mentioned factors is expected to drive the market for drug-eluting stents during the given forecast period from 2024 to 2030.

However, the risks and complications associated with drug-eluting stents, the stringent regulatory approval process, among others may prove to be challenging factors for the growth of the drug-eluting stents market.

Drug-Eluting Stents Market Segment Analysis:

Drug-Eluting Stents Market by Type (Coronary Stenting and Peripheral Stenting), Scaffold (Platinum-Chromium, Cobalt-Chromium, Nitinol, and Others), Coating (Polymer-based Coating [Biodegradable and Non-biodegradable] and Polymer-free Coating), Drug Type (Everomilus, Paclitaxel, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the coating segment of the drug-eluting stents market, the polymer-based coating category is expected to have a significant revenue share in 2023. This is due to the various features and applications of polymer-based coating of drug-eluting stents.

Polymer-based coatings on drug-eluting stents enhance the controlled release of therapeutic agents, making them highly effective in preventing restenosis in coronary arteries. These coatings are engineered to enable the gradual and targeted release of drugs, such as antiproliferative or anti-inflammatory agents, directly at the stent site. This helps in reducing smooth muscle cell proliferation and neointimal hyperplasia, which are common causes of restenosis. Additionally, polymers can be tailored for specific hydrophilicity and hydrophobicity, adjusting drug release rates to optimize therapeutic effects.

Applications of polymer-based coatings extend beyond coronary stents, as they are also used in peripheral artery disease, maintaining arterial patency in various vessels. Furthermore, these coatings can be combined with multiple drugs to address a broader range of complications, like restenosis and inflammation, providing versatile treatment options for different patient needs.

Therefore, the widespread uses of polymer-based coating, solidify the impact on the overall growth of the drug-eluting stents market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall drug-eluting stents market:

Among all the regions, North America is estimated to hold a significant revenue share in the drug-eluting stents market. This can be attributed to several factors including the high instances of CAD, myocardial infarction, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the drug-eluting stents market in the North America region during the forecast period from 2024 to 2030.

As per data provided by the National Institute of Health (2023), it stated that 20.5 million people in the US were living with CAD. Furthermore, according to data from the Centers for Disease Control and Prevention (2024), it was stated that 805,000 people in the US have a myocardial infarction (heart attack) every year on average. Furthermore, as per the same source, it was stated that heart disease is an umbrella term that encompasses numerous indications such as acute coronary syndrome, atherosclerosis, and congestive heart failure among others. Some of the key risk factors associated with heart disease are high blood cholesterol, high blood pressure, and smoking. The source further mentioned that about half of Americans (47%) have at least one of these three risk factors.

According to data from the Canadian Institute for Health Information (2024), it stated that in 2022, 2.4 million Canadians were affected by heart disease.

Since cardiovascular disorders are rising in the region among middle-aged individuals, the demand for more effective diagnostic and treatment options is increasing significantly. This trend is fueling investment in innovative technologies and expanding the market for drug-eluting stents.

Product developmental activities initiated by regulatory bodies will further boost the market for drug-eluting stents. For example, in March 2024, Boston Scientific Corporation announced that it received U.S. Food and Drug Administration (FDA) approval for the AGENT(TM) Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease.

The prompt and well-established healthcare services and infrastructure further contribute to the growth of the regional drug-eluting stents market growth. The presence of key players such as Abbott, Medtronic, and Boston Scientific Corporation with their strong distribution networks ensure widespread availability and accessibility of these devices across the region increasing their revenue shares in the market, and supportive reimbursement programs providing immense growth opportunities for the same.

Therefore, the interplay of all the factors mentioned above provides a conducive growth environment for the North America region in the drug-eluting stents market during the forecast period from 2024 to 2030.

Drug-Eluting Stents Market key players:

Some of the key market players operating in the drug-eluting stents market include Medtronic, Abbott, Boston Scientific Corporation, B. Braun Melsungen AG, BIOTRONIK SE & Co. KG, Cook, Terumo Corporation, Lepu Medical Technology Co., Ltd., Microport Scientific Corporation, Balton Sp.z.o.o, ENDOCOR GmbH, Eurocor Tech GmbH, Alvimedica, Biosensors International Group, Ltd., Meril Life Sciences Pvt. Ltd., Translumina, Sino Medical Sciences Technology Inc., iVascular S.L.U, Sahajanand Laser Technology Limited, Cardionovum GmbH, and others.

Recent Developmental Activities in the Drug-Eluting Stents Market:

• In September 2021, Biotronik received regulatory approval from the US Food and Drug Administration for their Orsiro Mission bioabsorbable polymer drug-eluting stent system (BP-DES).
• In June 2021, Abbott received product approval from the US FDA for their XIENCE family of stents for one-month (for 28 days) DAPT labeling for high bleeding risk (HBR) patients in the U.S.
• In May 2021, Alvimedica received the CE mark approval for their NiTides self-expanding, drug-eluting stent, aimed for treating lesions associated with peripheral artery disease in the superficial femoral arteries.

Key takeaways from the Drug-Eluting Stents Market Report study

• Market size analysis for current drug-eluting stents market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the drug-eluting stents market
• Various opportunities available for other competitors in the drug-eluting stents market space
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current drug-eluting stents market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for drug-eluting stents market growth in the coming future?

Target audience who can be benefited from this drug-eluting stents market report study

• Drug-eluting stents providers
• Research organizations and consulting companies
• Drug-eluting stents related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in drug-eluting stents
• Various end-users who want to know more about the drug-eluting stents market and the latest developments in the drug-eluting stents market

Frequently Asked Questions for the Drug-Eluting Stents Market:

1. What are drug-eluting stents?

• The drug-eluting stent is a small mesh structure that is inserted into the artery to keep it open and also releases a medication that helps in preventing the formation of blood clots inside the stent.

2. What is the market for drug-eluting stents?

• The drug-eluting stents market was valued at USD 2.40 billion in 2023, growing at a CAGR of 7.88% during the forecast period from 2024 to 2030 to reach USD 3.78 billion by 2030.

3. What are the drivers for the drug-eluting stents?

• The drug-eluting stents market is observing substantial market growth primarily owing to the increasing cases of cardiovascular disorders including atrial fibrillation and coronary artery disease (CAD), peripheral artery disease (PAD), innovative product developmental activities by regulatory bodies, and the rising adoption of minimally invasive techniques that are expected to escalate the overall growth of the drug-eluting stents market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the drug-eluting stents?

• Some of the major market players operating in the drug-eluting stents market include Medtronic, Abbott, Boston Scientific Corporation, B. Braun Melsungen AG, BIOTRONIK SE & Co. KG, Cook, Terumo Corporation, Lepu Medical Technology Co.,Ltd., Microport Scientific Corporation, Balton Sp.z.o.o, ENDOCOR GmbH, Eurocor Tech GmbH, Alvimedica, Biosensors International Group, Ltd., Meril Life Sciences Pvt. Ltd., Translumina, Sino Medical Sciences Technology Inc., iVascular S.L.U, Sahajanand Laser Technology Limited, Cardionovum GmbH, and others.

5. Which region has the highest share in the drug-eluting stents?

• Among all the regions, North America is estimated to hold a significant revenue share in the drug-eluting stents market. This can be attributed to several factors including the high instances of CAD, myocardial infarction, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the drug-eluting stents market in the North America region during the forecast period from 2024 to 2030.